Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma.
Sei MorinagaQinghong HanKohei MizutaByung Mo KangMotokazu SatoMichael BouvetNorio YamamotoKatsuhiro HayashiHiroaki KimuraShinji MiwaKentaro IgarashiTakashi HiguchiHiroyuki TsuchiyaSatoru DemuraRobert M HoffmanPublished in: Anticancer research (2024)
The present study showed that the combination of eribulin and rMETase can overcome high eribulin resistance of fibrosarcoma. The present results demonstrate that combining rMETase with first- or second-line therapy for soft-tissue sarcoma has the potential to overcome the intractable clinical problem of drug-resistant soft-tissue sarcoma.